Furthermore, the research of Pushkarev and Ukaji found that the combined use of paclitaxel and DHMEQ could inhibit the chemotherapy resistance of undifferentiated TC cells to paclitaxel; moreover, compared with common tumor cells, DHMEQ, as an NF-κB inhibitor, is more active in tumor ste0m cells [13, 14]. This evidence concerns the gene NFKB1 and neoplasm.